[HTML][HTML] Role of p53 in breast cancer progression: An insight into p53 targeted therapy

C Marvalim, A Datta, SC Lee - Theranostics, 2023 - ncbi.nlm.nih.gov
The transcription factor p53 is an important regulator of a multitude of cellular processes. In
the presence of genotoxic stress, p53 is activated to facilitate DNA repair, cell cycle arrest …

Traditional Chinese medicine: a treasured natural resource of anticancer drug research and development

CY Wang, XY Bai, CH Wang - The American journal of Chinese …, 2014 - World Scientific
To discover and develop novel natural compounds, active ingredients, single herbs and
combination formulas or prescriptions in traditional Chinese medicine (TCM) with …

Targeting the p53-MDM2 pathway for neuroblastoma therapy: Rays of hope

A Zafar, W Wang, G Liu, W Xian, F McKeon, J Zhou… - Cancer letters, 2021 - Elsevier
Despite being the subject of extensive research and clinical trials, neuroblastoma remains a
major therapeutic challenge in pediatric oncology. The p53 protein is a central safeguard …

Targeting the ubiquitin pathway for cancer treatment

J Liu, S Shaik, X Dai, Q Wu, X Zhou, Z Wang… - Biochimica et Biophysica …, 2015 - Elsevier
Proteasome-mediated degradation is a common mechanism by which cells renew their
intracellular proteins and maintain protein homeostasis. In this process, the E3 ubiquitin …

[HTML][HTML] Natural products for chemoprevention of breast cancer

EY Ko, A Moon - Journal of cancer prevention, 2015 - ncbi.nlm.nih.gov
Breast cancer is the primary cause of cancer death in women. Although current therapies
have shown some promise against breast cancer, there is still no effective cure for the …

[HTML][HTML] Natural products targeting the p53-MDM2 pathway and mutant p53: recent advances and implications in cancer medicine

JJ Qin, X Li, C Hunt, W Wang, H Wang, R Zhang - Genes & diseases, 2018 - Elsevier
The p53 tumor suppressor plays a major role in controlling the initiation and development of
cancer by regulating cell cycle arrest, apoptosis, senescence, and DNA repair. The MDM2 …

Ginsenoside 20 (S)-Rg3 targets HIF-1α to block hypoxia-induced epithelial-mesenchymal transition in ovarian cancer cells

T Liu, L Zhao, Y Zhang, W Chen, D Liu, H Hou, L Ding… - PLoS …, 2014 - journals.plos.org
The prognosis of patients with ovarian cancer has remained poor mainly because of
aggressive cancer progression. Since epithelial-mesenchymal transition (EMT) is an …

Panax notoginseng saponins (PNS) inhibits breast cancer metastasis

P Wang, J Cui, X Du, Q Yang, C Jia, M Xiong… - Journal of …, 2014 - Elsevier
Abstract Ethnopharmacological relevance Panax notoginseng (Burkill) FH Chen
(Araliaceae) has been extensively used as a therapeutic agent to treat a variety of diseases …

The pyrido[b]indole MDM2 inhibitor SP-141 exerts potent therapeutic effects in breast cancer models

W Wang, JJ Qin, S Voruganti, KS Srivenugopal… - Nature …, 2014 - nature.com
A requirement for Mouse Double Minute 2 (MDM2) oncogene activation has been
suggested to be associated with cancer progression and metastasis, including breast …

Modulation of hypoxia-inducible factor-1 signaling pathways in cancer angiogenesis, invasion, and metastasis by natural compounds: a comprehensive and critical …

S Fakhri, SZ Moradi, F Faraji, L Kooshki… - Cancer and Metastasis …, 2024 - Springer
Tumor cells employ multiple signaling mediators to escape the hypoxic condition and trigger
angiogenesis and metastasis. As a critical orchestrate of tumorigenic conditions, hypoxia …